Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from...

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced findings from two new analyses of the landmark EMPA-REG OUTCOME® trial, presented at the 78th American Diabetes...

With women's health, obstetric and neonatal nurses taking on ever-greater responsibilities, there's no better time than AWHONN's 2018 annual convention, from today through June 27 in Tampa, to see...

Xultophy® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL provided superior A1C reduction compared to insulin glargine U-100 (1.94% vs 1.68% respectively;...

ViaCyte, Inc., a privately-held regenerative medicine company, today announced two-year data from Cohort 1 of the ongoing Safety, Tolerability, and Efficacy of VC-01™ (PEC-Encap™) Product...

Amgen (NASDAQ:AMGN) today announced new data that show Repatha® (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol...

Two investigational doses of Lilly's dulaglutide (4.5 mg and 3.0 mg), as well as Trulicity® (dulaglutide) 1.5 mg, provided significantly better blood sugar control with weight benefits compared...

Array BioPharma Inc. (NASDAQ: ARRY) today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of...

TBWA\Worldwide delivered one of its best performances in years at the Cannes Lions International Festival of Creativity, winning Gold or higher in 10 distinct categories and bringing home a total...

Silicon Valley Blockchain Developer Hackathon -- F50, Blockchain Founder Club, and Silicon Valley Entrepreneurs & Startup (SVE), announced their joint effort to organize Founder World 2018:...